COMMUNIQUÉS West-GlobeNewswire

Elevar Therapeutics Submits New Drug Application to FDA for Lirafugratinib as Second-Line Treatment Option for Cholangiocarcinoma
28/01/2026
FORT LEE, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and [...]
MEDVI Quad Prescription Information Updated as Consumer Interest in Prescription Erectile Dysfunction Treatment Access Through Telehealth Platforms Grows in 2026
28/01/2026
An informational overview examining category context, publicly available service disclosures, and what consumers often consider when researching prescription erectile dysfunction treatment access through telehealth [...]
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
28/01/2026
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in relapsed/ [...]
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
28/01/2026
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600 ® Index. The inclusion will [...]
Women’s Health Collective Canada Announces Vital Talks Event on Menstruation and Lifelong Hormonal Health, Presented by Vichy Laboratoires
28/01/2026
From menstrual cycles to menopause and beyond – experts explore how hormones shape health at every stage of life TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Women’s Health Collective Canada is pleased to announce the [...]
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
28/01/2026
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
STERIS Announces Dividend of $0.63 per share
28/01/2026
DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on [...]
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease
28/01/2026
- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program - HUNTSVILLE, AL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or [...]
NADP Foundation Announces 2026 Grants
28/01/2026
DALLAS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The National Association of Dental Plans (NADP) Foundation is pleased to announce the recipients of its 2026 grant awards, supporting innovative projects that improve access to [...]
Siren Biotechnology Announces FDA Clearance of First IND, Advancing Company to Clinical Stage
28/01/2026
SAN FRANCISCO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s [...]
Memorial Şişli Hospital Earns EARL “Theranostics Center of Excellence” for Nuclear Oncology Treatments
28/01/2026
ISTANBUL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Memorial Şişli Hospital’s (part of Memorial Hospitals Group ) Nuclear Medicine Department, Theranostics Unit has successfully completed the evaluation process under the [...]
GUERBET : Karim Boussebaa nommé Directeur général
28/01/2026
Karim Boussebaa nommé Directeur général de Guerbet Villepinte, le 28 janvier 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce la nomination [...]
Guerbet: Karim Boussebaa appointed Chief Executive Officer
28/01/2026
Karim Boussebaa Appointed Chief Executive Officer of Guerbet Villepinte, January 28, 2026: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the appointment [...]
COUR Pharma Publishes Peer-Reviewed Data in Science Advances
28/01/2026
Paper defines the mechanism by which COUR Nanoparticles induce antigen-specific immune tolerance CHICAGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing ﬁrst-in-class, [...]
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
28/01/2026
-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its [...]
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease
28/01/2026
• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein [...]
Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies
28/01/2026
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials BOSTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Life Biosciences , Inc., (“Life Bio”) a [...]
Bexorg Awarded Grant from The Michael J. Fox Foundation to Identify Translational Biomarkers for TRPML1-Targeted Parkinson’s Disease Therapies
28/01/2026
- TRPML1 is a promising target 1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in clinical studies - Bexorg will leverage its postmortem whole-human [...]
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
28/01/2026
PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report [...]

Pages